Ann: VitroGro Sales Planned to Start in June 2012, page-44

re: Ann: VitroGro Sales Planned to Start in J... Resourced, I do accept you are not trying to downramp TIS, but are a genuine TIS shareholder who wants it to do well.

By your comment that approval 2 months earlier would be "at the expense of merely having to relabel stock", you clearly have not understood the strategic reasons why TIS chose to delay. When TIS made the decision to delay the approval application by two months, the advantages for TIS were believed to be substantial (two more months of product for sale with no further manufacturing cost, when sales would have already ramped up in Europe). It was only very recently that TIS became aware that relabeling was not economic, hence the need for the new announcement. There was no reason to inform the market about the delay in application as it alone did not change the commencement of sales date already announced. Its decision to delay the application for the CE Mark by two months did not substantively change the already announced sales start date. The delay of a few weeks from early June to late June was due to recruitment issues for its partner (approval still expected before early June).

So please, give TIS management a bit more credit. Don't forget that the TIS Chairman has 4.6M shares and Steve Mercer has over 1M shares in TIS. I think we can trust them to do the right thing for shareholders.

I also don't accept your comment that TIS is releasing "spin" and I cannot understand why you are so negative about TIS's communications to shareholders, given the limited funding and resources it currently has as a sub $100M stock with limited funds. Surely as a shareholder, you must agree that the results it has been achieving have been substantial (e.g. great EU trial, and all audits and requirements necessary for EU approval).

When the cash flow starts in earnest, I have no doubt that TIS will appoint more staff to better deal with shareholder communications. In the meantime, please give them a break and concentrate on the bigger picture concerning market entries, sales and earnings growth.